HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 167 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $452,000 | -81.0% | 10,272 | -82.8% | 0.03% | -78.2% |
| Q1 2022 | $2,384,000 | +67.9% | 59,782 | +69.3% | 0.16% | -11.9% |
| Q4 2021 | $1,420,000 | +55.9% | 35,318 | +57.6% | 0.18% | +46.3% |
| Q3 2021 | $911,000 | -42.5% | 22,405 | -74.9% | 0.12% | -74.4% |
| Q4 2019 | $1,584,000 | +63.3% | 89,363 | +42.8% | 0.47% | +30.7% |
| Q3 2019 | $970,000 | -15.1% | 62,562 | -6.0% | 0.36% | -14.2% |
| Q2 2019 | $1,143,000 | +54.5% | 66,537 | +44.8% | 0.42% | -0.2% |
| Q1 2019 | $740,000 | -48.7% | 45,965 | -53.4% | 0.42% | +5.2% |
| Q4 2018 | $1,443,000 | +21.5% | 98,601 | +50.8% | 0.40% | +57.0% |
| Q3 2018 | $1,188,000 | +64.5% | 65,394 | +52.9% | 0.26% | +70.7% |
| Q2 2018 | $722,000 | +54.6% | 42,769 | +79.5% | 0.15% | +66.7% |
| Q1 2018 | $467,000 | +253.8% | 23,830 | +56.0% | 0.09% | +66.7% |
| Q2 2016 | $132,000 | – | 15,272 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
| First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
| SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
| Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
| Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
| Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
| DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
| Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
| Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |